Modifies provisions relating to the administration of eye drops to newborn infants
Summary
HB 2972 revises Missouri law governing the administration of erythromycin eye drops to newborn infants. Under current law, the medication is generally used as a prophylactic treatment to prevent eye infections contracted during birth. This bill changes the treatment from a routine practice to one that may be given only if informed consent is obtained from the infant’s parent or legal guardian and documented. It also requires a written report of the administration and the consent documentation to be sent to the local public health agency within 48 hours.
The bill further provides that a parent or guardian’s refusal to consent cannot be used as a basis to contact state agencies, including the children’s division of the Department of Social Services. If a state agency is contacted in violation of that protection, the parent or guardian may bring a civil action in circuit court and recover costs and reasonable attorney’s fees if successful. The bill also replaces criminal penalties with professional discipline for providers who administer the drops without the required consent: a first violation results in a written warning, a second in a $5,000 fine and one-year license suspension, and a third or subsequent violation in a $5,000 fine and license revocation.
Impact
HB 2972 would amend sections 210.070 and 210.100 of the Missouri Revised Statutes, narrowing the circumstances under which erythromycin eye drops may be administered to newborns and adding consent, reporting, and enforcement requirements. It would shift the legal framework from a general prophylactic newborn-care requirement to a consent-based model, while also limiting criminal liability and creating civil and professional-licensing consequences for noncompliance. The bill would affect physicians, midwives, nurses, public health agencies, and parents or legal guardians of newborns.
Sentiment
Based on the bill text and available context, the measure appears to be framed as a parental-rights and informed-consent bill rather than a public-health mandate. No committee transcript or vote record is available, so there is no documented floor or committee debate to gauge broader legislative sentiment. The language suggests support for limiting state involvement in newborn treatment decisions and for protecting providers from criminal penalties, while still preserving a reporting mechanism and professional accountability.
Contention
The main point of contention is the balance between newborn public-health prophylaxis and parental informed consent. Supporters of the bill would likely favor the requirement that erythromycin eye drops be administered only with documented consent and the prohibition on state-agency referral when parents refuse treatment. Opponents would likely argue that making the treatment optional could reduce a standard preventive measure for newborn eye infections and that the bill’s restrictions on contacting state agencies may limit child-welfare responses in medical disputes. The bill also raises questions about whether professional discipline, rather than criminal penalties, is an adequate enforcement mechanism.